PRKCA and Alzheimer disease: In the present study, we used genome editing to introduce the M489V gain-of-function variant into endogenous PKCα in order to determine whether this single amino acid change, modestly enhancing kinase activity, is sufficient to drive the pathology of AD in a mouse model.